← All trials
NCT04513639
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2020
- Primary completion
- Jun 1, 2030
- Completion date
- Jun 1, 2031
- First posted
- Aug 14, 2020
- Last posted
- Aug 14, 2020
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloOverall official - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- University of StavangerCollaborator
- University Hospital of North NorwayCollaborator
- Sykehuset OstfoldCollaborator
- The Hospital of VestfoldCollaborator
- Oslo Metropolitan UniversityCollaborator
- Sorlandet Hospital HFCollaborator
- University of BergenCollaborator
- Helse Møre og Romsdal HFCollaborator
- Nordland HospitalCollaborator
- Levanger HospitalCollaborator
- Helse FordeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.